Taken together, high therapeutic doses of C1-INH are likely required for the treatment of HAE to offset its limited potency and broad specificity and may account for the occurrence of breakthrough attacks with current prophylactic approaches (70). This evidence concerns the gene SERPING1 and hereditary angioedema.